



At a
Glance 2021

Fresenius invested **€748 million** in research and development last year.




Sales and Earnings <small>in € millions</small>	2020	2019	Growth
Sales	36,277	35,409	2%
EBIT	4,612	4,688	-2%
EBIT margin	12.7%	13.2%	
Net income	1,796	1,879	-4%
Operating cash flow	6,549	4,263	54%

Employees	2020	2019	
Employees (Dec. 31)	311,269	294,134	6%



Fresenius is a **global healthcare group** offering high-quality products and services for dialysis, hospitals, and outpatient treatment. With over 300,000 employees in more than 100 countries around the globe and annual sales exceeding €36 billion, Fresenius is one of the world’s leading healthcare companies.

At Fresenius, the **patient always comes first**. For more than 100 years now we have been working to save lives and improve the quality of life of our patients. A clear **focus on innovation and efficiency** has helped us to make high-quality healthcare accessible to a steadily increasing number of people. Yet we never get complacent about our successes, and never stop looking for better solutions. This is how Fresenius is contributing to **medical progress** and better patient care.

“Forward Thinking Healthcare” captures our commitment to the future: **better medicine for more people**.



Dancing against COVID

Fresenius Helios and its employees took up the Jerusalem Challenge to show solidarity in a difficult time.



Production expansion in pandemic

Fresenius Medical Care opened a new production line for dialysis fluids at its St. Wendel, Germany plant in June. Work on the new line was accelerated to meet higher demand for solutions needed to carry out acute dialysis, resulting from an increase in acute kidney failure cases caused by COVID-19.

In battle against the coronavirus

The COVID-19 pandemic confronted Fresenius with unprecedented challenges. The company took extensive measures to ensure that millions of patients worldwide continued to receive high-quality healthcare.

Fresenius Helios significantly increased the number of intensive-care beds in its hospitals. Helios medical teams from Germany traveled to support their colleagues in Spain, and several of Helios' German hospitals admitted patients from Italy and France. In order to secure important data for research into the virus, the company established a multi-center COVID-19 register.



Our year 2020



Fresenius Medical Care partnered with other dialysis providers in the United States to create isolation capacity for the joint treatment of dialysis patients with confirmed or possible COVID-19 infections. And the company increased production of urgently needed equipment and products for lung-replacement therapy and acute dialysis. Fresenius Kabi stepped up production of important medicines for which demand has risen sharply during the pandemic, such as the anesthetic propofol. In Austria, Fresenius Vamed is using resources from its rehabilitation facilities and clinics to help relieve acute care hospitals.

Approval in the U.S.

Fresenius Medical Care received Food and Drug Administration clearance in February for Novalung, the company's heart and lung support system for the treatment of acute respiratory or cardiopulmonary failure.



New biosimilar


Fresenius Kabi applied for regulatory approval of its second biosimilar in the U.S. and Europe in the spring. The medication, pegfilgrastim, is for use in cancer treatment.



Acquisition of Eugin Group

Fresenius Helios acquired the Eugin Group, a leading international group in the field of fertility treatments, in December. Eugin Group's network comprises 31 clinics and 34 other sites in nine countries on three continents. Fresenius Helios also acquired five additional hospitals in Germany and Colombia.

Products and services for individuals with renal diseases



Fresenius Medical Care
has already produced more than

2 billion
dialysis filters.




Key Figures in € millions	2020	2019	Growth
Sales	17,859	17,477	2%
EBIT	2,499	2,356	6%
Net income	1,359	1,236	10%
Operating cash flow	4,233	2,567	65%
Capital expenditure/ acquisitions	1,459	3,422	-57%
R & D expenses	194	168	15%
Employees (Dec. 31)	133,129	128,300	4%



Fresenius Medical Care is the world's largest provider of **products and services** for individuals with **renal diseases** of which more than 3.7 million patients worldwide regularly undergo dialysis treatment.

Through its network of more than 4,000 dialysis clinics, Fresenius Medical Care provides dialysis treatments for over 346,500 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines and dialyzers.

Along with its core business, the company offers additional medical services in the field of Care Coordination.



In 2020, Fresenius Medical Care provided

around **54 million**
dialysis treatments to patients.



Products for critically and chronically ill patients




Key Figures <small>in € millions</small>	2020	2019	Growth
Sales	6,976	6,919	1%
EBIT	1,095	1,205	-9%
Net income	730	797	-8%
Operating cash flow	1,143	1,028	11%
Capital expenditure/ acquisitions	718	812	-12%
R & D expenses	553	507	9%
Employees <small>(Dec. 31)</small>	40,519	39,627	2%



Fresenius Kabi specializes in lifesaving medicines and technologies for **infusion, transfusion and clinical nutrition**. The company's products and services are used to help care for critically and chronically ill patients.

Fresenius Kabi's product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for the collection of blood components and in therapies.



More than **1 million** infusion and clinical nutrition pumps from Fresenius Kabi are in use worldwide.

Europe's leading private hospital operator

Fresenius Helios treats around **20 million** patients annually.




Key Figures <small>in € millions</small>	2020	2019	Growth
Sales	9,818	9,234	6%
EBIT	1,025	1,025	0%
Net income	666	664	0%
Operating cash flow	1,149	733	57%
Capital expenditure/ acquisitions	1,000	693	44%
Employees <small>(Dec. 31)</small>	116,952	106,377	10%

Fresenius Helios is **Europe's leading private hospital operator**, with more than 100,000 employees. Fresenius Helios owns and operates Helios hospitals in Germany and Quirónsalud hospitals in Spain. Both Helios and Quirónsalud are the largest private hospital operators in their respective national markets.

Helios owns 89 hospitals across Germany - including maximum care facilities in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal.

Quirónsalud operates over 50 hospitals, more than 70 outpatient centers and some 300 occupational risk centers.



Some **70,000** births take place in Fresenius Helios hospitals annually.



Projects and services for health care facilities

Worldwide, Fresenius Vamed provides **820**
technical services to some
health care facilities with a total of
207,000 patient beds.




Key Figures in € millions	2020	2019	Growth
Sales	2,068	2,206	-6%
EBIT	29	134	-78%
Net income	2	83	-98%
Operating cash flow	78	-17	--
Capital expenditure/ acquisitions	101	85	19%
Order intake	1,010	1,314	-23%
Employees (Dec. 31)	19,414	18,592	4%



Fresenius Vamed is a leading global provider of **services for hospitals and other health care facilities**. Its portfolio ranges from project development and planning to the total operational management of health care facilities and providing services to patients. The services are aimed at various areas of health care, ranging from prevention to acute care, rehabilitation and nursing.

Headquartered in Vienna, Austria, Fresenius Vamed has successfully completed some 1,000 health care projects in 95 countries on five continents since the company's founding in 1982.





Fresenius Vamed is responsible for the total operational management of **100** health care facilities.



311,269

■ Employees
at end of 2020




■ Sales
in 2020

€36.3 billion



32%
of managers at
Fresenius are women.



Our commitment to sustainability is focused on six major areas:



A commitment to operating responsibly and sustainably is part of our company's business culture, and of the way we work every day. Living up to our legal and ethical responsibilities as a globally active company is important to us. That is why, in 2020, Fresenius established a **Group-wide Sustainability Council** to address issues with social, compliance and environmental implications.

Fresenius is committed to the Sustainable Development Goals of the United Nations. Our most significant positive impact is on three of these goals: **Good Health and Well-Being, Quality Education, and Decent Work and Economic Growth.**





Financial Calendar

Publication of 2020 business results	February 23, 2021
Results Q1/21	May 6, 2021
Annual General Meeting	May 21, 2021
Dividend payment	May 27, 2021*
Results Q2/21	July 30, 2021
Results Q3/21	November 2, 2021

*Subject to approval by the Annual General Meeting on May 21, 2021

From a local pharmacy
to a global corporation

1462

Opening of the Hirsch Pharmacy in Frankfurt

In the 19th century, ownership of the pharmacy passes to the Fresenius family.



1912

Founding of the company

The pharmacist Dr. Eduard Fresenius, proprietor of the Hirsch Pharmacy, establishes the pharmaceutical company Dr. E. Fresenius.



1952

Else Kröner assumes management of Fresenius

The foster daughter of Eduard Fresenius will, along with her future husband Hans Kröner, build the company into a global healthcare group over the following decades.

1946

Death of the company's founder, Eduard Fresenius



1966

Distributor of dialysis machines

Fresenius starts to sell dialysis machines and dialyzers manufactured by various non-German companies.



1994

Entry into project business

With the acquisition of Hospitalia International, Fresenius enters the project business to develop hospitals and other healthcare facilities.

1986

Fresenius listed on stock market

1979

Development and sale of company's own dialysis machines

Production of the A2008 dialysis machine begins in a newly acquired factory in Schweinfurt, Germany.



1996

Entry into Dialysis Services

Fresenius Medical Care is created when the U.S. dialysis provider National Medical Care, acquired by Fresenius, is merged with Fresenius' own dialysis business.

The project business is expanded with the acquisition of VAMED AG.



2005

Expansion of hospital business

Fresenius acquires Helios, one of Germany's leading private hospital operators.



2008

Expansion in I.V. generics

Fresenius Kabi enters the North American pharmaceuticals market through the acquisition of APP Pharmaceuticals.

1999

Expansion of infusions business

The nutrition business of Pharmacia & Upjohn is acquired and then merged with Fresenius Pharma to form Fresenius Kabi.



2017

Hospital network expanded outside of Germany

Fresenius Helios acquires Quirónsalud, Spain's largest private hospital operator.



2020

Active around the world

With more than 300,000 employees in over 100 countries, Fresenius is one of the world's leading healthcare companies.

Fresenius SE & Co. KGaA

Else-Kröner-Str. 1
61352 Bad Homburg
Germany

T +49 6172 608-0
www.fresenius.com

Contact for Media

Corporate Communications
T +49 6172 608-2302
pr-fre@fresenius.com

Contact for Shareholders

Investor Relations
T +49 6172 608-2487
ir-fre@fresenius.com

Contact for Job Applicants

HR Marketing
 +49 172 7407809
careers@fresenius.com



www.fresenius.com/socialmedia

Some figures adjusted for special items and on a comparable basis.
Net income = Net income attributable to the parent company of the
respective business segment.

